Abstract: In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
November 23, 2021
Assignee:
University of Central Florida Research Foundation, Inc.
Inventors:
Annette Khaled, Rebecca Boohaker, Michael Lee, Jesus Perez Figueroa
Abstract: This disclosure provides non-naturally occurring collagen and elastin molecules. The non-naturally occurring collagens and elastins include truncated collagens, truncated elastins, as well as fusion proteins thereof. The non-naturally occurring collagen and elastin are useful in foods, cosmetics and many other products and uses.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
November 23, 2021
Assignee:
GELTOR, INC.
Inventors:
Nikolay Ouzounov, Alexander Lorestani, Monica Bhatia
Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
Type:
Grant
Filed:
July 29, 2019
Date of Patent:
November 9, 2021
Assignees:
The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
Abstract: This disclosure provides non-naturally occurring truncated elastin molecules. The non-naturally occurring truncated elastin may improve the firmness, elasticity, brightness, hydration, tactile texture, and/or visual texture of skin. The non-naturally occurring truncated elastin may reduce degradation of the extracellular matrix.
Abstract: The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.
Type:
Grant
Filed:
July 7, 2016
Date of Patent:
November 9, 2021
Assignees:
INSTITUTO MASSONE S.A.
Inventors:
Miguel Angel Castellano, José F. Groisman, Liliana Ester Balanian, Felipe Inserra, Emilio Sojo, Claudio Fernando Wolfenson Band, Elena M. V. de Cavanagh
Abstract: The invention is directed to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, a HIV fusion peptide inhibitor moiety and combinations thereof. More specifically, the present invention relates to polypeptides comprising a fibronectin-based scaffold domain protein that binds CD4, a fibronectin-based scaffold domain protein that binds the N17 domain of gp41, and a HIV fusion peptide inhibitor or combinations thereof. The invention also relates to the use of the innovative proteins in therapeutic applications to treat HIV.
Type:
Grant
Filed:
August 7, 2019
Date of Patent:
October 26, 2021
Inventors:
Mark R. Krystal, David L. Wensel, Jonathan Davis
Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
Abstract: The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
Type:
Grant
Filed:
December 11, 2017
Date of Patent:
September 28, 2021
Assignee:
Zealand Pharma A/S
Inventors:
Bjarne Due Larsen, Lise Giehm, Alistair Vincent Gordon Edwards
Abstract: The present invention relates to novel antimicrobial peptide and variants thereof. The invention further relates to method of killing or inhibiting growth of microbes and use of the peptide here disclosed as a medicament, feed additive, preservative or surfactant.
Type:
Grant
Filed:
January 13, 2020
Date of Patent:
August 24, 2021
Assignee:
Chain Antimicrobials Oy
Inventors:
Tejesvi Mysore Vishakante Gowda, Anna Maria Pirttilä
Abstract: The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating autoimmune disease using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.
Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
Type:
Grant
Filed:
September 4, 2018
Date of Patent:
July 13, 2021
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Hans P. Maerki, Benoit Hornsperger, Peter Mohr, Michael Reutlinger, Roberto Iacone
Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
June 29, 2021
Assignee:
Regeneren Pharmaceuticals, Inc.
Inventors:
Yang Wei, Haruka Okamoto, Jesper Gromada, Samuel Davis, Andrew J. Murphy
Abstract: This disclosure provides non-naturally occurring collagen and elastin molecules. The non-naturally occurring collagens and elastins include truncated collagens, truncated elastins, as well as fusion proteins thereof. The non-naturally occurring collagen and elastin are useful in foods, cosmetics and many other products and uses.
Type:
Grant
Filed:
April 2, 2020
Date of Patent:
June 8, 2021
Assignee:
GELTOR, INC.
Inventors:
Nikolay Ouzounov, Alexander Lorestani, Monica Bhatia
Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
Abstract: The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Abstract: Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.
Abstract: The object of the present invention relates to a novel family of peptide conjugates of formula (I): A-X1-X2-Pro-Ala-X—B??(I) wherein: A represents a hydrogen atom, a C6 to C20 acyl group or a cholesterol residue; X1 represents a covalent bond, an alanine or a proline; X2 represents an arginine, a lysine, or an alanine; X represents a lysine, an alanine, or a phenylalanine; and B represents a hydroxyl or an amine; or one of its preferentially pharmaceutically, dermatologically or cosmetically acceptable salts, as well as their synthesis processes and their uses for reducing hair loss and stimulating hair growth.
Type:
Grant
Filed:
October 10, 2016
Date of Patent:
March 16, 2021
Assignees:
Institut European de Biologic Cellulaire, Centre de Recherches Biologiques et d'Experimentations Cutanees, Centre National de la Recherche Scientifique (CNRS)
Abstract: A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NOs: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NOs: 15 to 505, and 546 to 704.
Abstract: The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.
Abstract: The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on binding of dynamin-1-related protein (Drp1) GTPase activity, Drp1 to mitochondrial fission 1 protein (Fis1), reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture.
Type:
Grant
Filed:
January 4, 2018
Date of Patent:
February 9, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University